Clover Biopharma Gets Critical Cash Booster After Covid Vaccine Approval
The innovative drug maker announced a major share sale a day after its self-developed Covid-19 vaccine got the green light for emergency use in ChinaKey Takeaways:Clover Biopharmaceuticals raised $64 million…
AIM Vaccine Shrinks Its IPO But Gives Chairman a Mega Paycheck
China’s second-largest maker of non-Covid vaccines has finally crossed the IPO finish line and will list its shares next Thursday Key Takeaways: AIM Vaccine is finally landing on the Hong…
AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt
Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
FAST NEWS: Vaccine Maker Jiangsu Recbio Gets Little Boost on Listing Day
The latest: Jiangsu Recbio Technology Co. Ltd (2179.HK), a producer of human papillomavirus (HPV) vaccines, received a muted reception as it made its trading debut in Hong Kong on Thursday.…
Recent Articles
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
